

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>					Complete if Known				
					Application Number		09/699,131 10/705,448		
					Filing Date		October 26, 2000		
					First Named Inventor		Joseph L. Witztum		
					Group Art Unit		Unknown 1641		
					Examiner Name		Unknown LY/Cook		
Sheet		2	of	2	Attorney Docket Number		6627-PA0045		
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ²		
L/C	4	Hörkkö, S., Miller, E., Dudi, E., et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized LDL. <i>J. Clin. Invest.</i> 1996;98:815-825.							
	5	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. <i>Science</i> . 1989;246:1275-1281.							
	6	Palinski, W., Hörkkö, S., Miller et al: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apo E-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. <i>J. Clin. Invest.</i> 1996;98:800-814.							
	7	Shaw, P.X., Hörkkö, S., Chang, M-K., Curtiss, L.K., Palinski, W., Silverman, G.J. and Witztum, J.L. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. <i>J. Clin. Invest.</i> 105:1731-40, 2000.							
	8	Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, Mab, identifies native atherosclerotic lesions in vivo. <i>J Nucl Cardiol.</i> 1999;6:41-53.							
L/C	9	Wu CC, Chang SW, Chen MS, Lee YT. Early change of vascular permeability in hypercholesterolemic rabbits. <i>Arterioscler Thromb Vasc Biol.</i> 1995;15:529-533.							
Examiner		<i>Miss J. Cook</i>					Date Considered	12/23/05	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/699,13T 10/705,448
(Use as many sheets as necessary)				Filing Date	10/26/2000
				First Named Inventor	Joseph L. Witztum
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	1	of	1	Attorney Docket Number	6627-PA0045

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
L/C	10	Libby, P. et al. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine, Vol. 8, No. 11, 1257-1262, Nov. 2002			
	11	Narula, J., et al. Strategic targeting of atherosclerotic lesions. Journal of Nuclear Cardiology, Part 1, pp. 81-90, Jan./Feb. 1999			
L/C	12	Strauss, H.W. Imaging of atherosclerosis – A worthy challenge. Journal of Nuclear Cardiology, Vol. 3, No. 3, pp. 278-280, May/June 1996			

Examiner Signature		Date Considered	12/23/05
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND T : Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
is a collection of information; unless it contains a valid OMB control number
it is subject to the Paperwork Reduction Act.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete If Known	
Application Number	10/705,448
Filing Date	11/11/2003
First Named Inventor	WITZTUM et al
Art Unit	unknown 1641
Examiner Name	unknown LYCOOL
Attorney Docket Number	6627-P0045C

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ "Kind Code ⁵ (if known)				
LYC	4	WO/98/21581	5-22-1998	Tsimikas et al	whole document	
LYC	5	WO 94/23302	10-13-1994	Selley	whole document	

Examiner
Signature

Alon L. Cook

Date
Considered

12/23/05

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Communications for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Application Number	10/705,448	
Filing Date	11/11/2003	
First Named Inventor	WITZTUM et al	
Art Unit	unknown 1641	
Examiner Name	unknown L Cook	
Attorney Docket Number	6627-P0045C	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
L/C	6	Hoorko S, Miller, E, Dudi E, et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids:recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized LDL. J. Clin. Invest.;1996;98: 815-825	
	7	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. Science . 1989;246:1275-1281	
	8	Palinski W, Horkko, S, Miller et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins for apo E-deficient mice. Demonstration of epitopes of oxidized LDL in human plasma. J.Clon.Invest 1996;98:800-814	
	9	Shaw P.X, Horkko, S, Chang, M-K Curtiss, L.K. Palinski, W, Silverman, G.J. and Witztum, J.L. Natural antibodies with T15 Idiotype may act in atherosclerosis, apoptotic clearance and protective immunity. J. Clin. Invest. 105:1731-40, 2000	
	10	Wu CC, Chang SW, Chen MS, Lee YT. Early change of vascular permeability in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1995, 15:529-533	
	11	Libby P. et al. Stabilizing of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine. Vol 8, No. 11, 1257-1262-Nov. 2002	
	12	Narula, J. et al. Strategic targeting of atherosclerotic lesions. Journal of Nucelar Cardiology, Part 1, pp. 81-90 Jan./Feb 1999	
	13	Strauss, H.W. Imaging of atherosclerosis-A worthy challenge. Journal of Nucelar Cardiology, Vol 3, No 3, pp.278-280 May/June 1996	
	14	Tsimikas, S. et al. In vivo uptake of Radiolabeled MDA2, an oxidation-specific monoclonal antibody provides an accurate measure..Arterioscler Thromb, Vasc. Biol., Vol 20:689-697.2006	
L/C	15	Holovet, P. et al, Monodialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin Invest. Vol 95:2611-9. 1995	

Examiner Signature	<i>Glenda Cook</i>	Date Considered	12/23/05
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/705,448
		Filing Date	11/11/2003
		First Named Inventor	WITZTUM et al
		Art Unit	unknown 1641
		Examiner Name	unknown L/COOK
Sheet 3	of 3	Attorney Docket Number	6627-P0045C

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	12/23/05
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached.
This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.